Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients

PLoS ONE

Volumn 12, Issue 4, 2017, Pages

  Linedale, Richard ^a   Schmidt, Campbell ^a,b   King, Brigid T ^a   Ganko, Annabelle G ^a   Simpson, Fiona ^a   Panizza, Benedict J ^a,b   Leggatt, Graham R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; HAVCR2 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER TISSUE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; NATURAL KILLER CELL; NATURAL KILLER T CELL; PERINEURAL INVASION; PERINEURAL SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; CARCINOMA, SQUAMOUS CELL; COHORT ANALYSIS; CRANIAL NERVE; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD274; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; CRANIAL NERVES; CTLA-4 ANTIGEN; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 85018474413     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0175755     Document Type: Article

References (36)

1. Lai SY, Weber RS. High-risk non-melanoma skin cancer of the head and neck. Curr Oncol Rep. 2005; 7 (2):154-8. Epub 2005/02/19. PMID: 15717950
2. Panizza BJ. An Overview of Head and Neck Malignancy with Perineural Spread. J Neurol Surg B Skull Base. 2016; 77(2):81-5. Epub 2016/04/29. PubMed Central PMCID: PMC4846415. https://doi.org/10. 1055/s-0036-1579778 PMID: 27123383.
3. Roh J, Muelleman T, Tawfik O, Thomas SM. Perineural growth in head and neck squamous cell carcinoma: a review. Oral Oncol. 2015; 51(1):16-23. Epub 2014/12/03. PubMed Central PMCID: PMC4268058. https://doi.org/10.1016/j.oraloncology.2014.10.004 PMID: 25456006
4. Gandhi M, Sommerville J. The Imaging of Large Nerve Perineural Spread. J Neurol Surg B Skull Base. 2016; 77(2):113-23. Epub 2016/04/29. PubMed Central PMCID: PMC4846417. https://doi.org/10. 1055/s-0036-1571836 PMID: 27123387
5. Gandhi MR, Panizza B, Kennedy D. Detecting and defining the anatomic extent of large nerve perineural spread of malignancy: comparing "targeted" MRI with the histologic findings following surgery. Head Neck. 2011; 33(4):469-75. Epub 2010/07/21. https://doi.org/10.1002/hed.21470 PMID: 20645285
6. Gupta A, Veness M, De'Ambrosis B, Selva D, Huilgol SC. Management of squamous cell and basal cell carcinomas of the head and neck with perineural invasion. Australas J Dermatol. 2016; 57(1):3-13. Epub 2015/03/12. https://doi.org/10.1111/ajd.12314 PMID: 25759949
7. Panizza B, Solares CA, Redmond M, Parmar P, O'Rourke P. Surgical resection for clinical perineural invasion from cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2012; 34 (11):1622-7. Epub 2012/01/04. https://doi.org/10.1002/hed.21986 PMID: 22213542
8. Warren TA, Panizza B, Porceddu SV, Gandhi M, Patel P, Wood M, et al. Outcomes after surgery and postoperative radiotherapy for perineural spread of head and neck cutaneous squamous cell carcinoma. Head Neck. 2016; 38(6):824-31. Epub 2014/12/30. https://doi.org/10.1002/hed.23982 PMID: 25546817
9. Wolf GT, Chepeha DB, Bellile E, Nguyen A, Thomas D, McHugh J. Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study. Oral Oncol. 2015; 51(1):90-5. Epub 2014/10/07. PubMed Central PMCID: PMC4268429. https://doi.org/10.1016/j.oraloncology.2014. 09.006 PMID: 25283344
10. Partlova S, Boucek J, Kloudova K, Lukesova E, Zabrodsky M, Grega M, et al. Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology. 2015; 4(1):e965570. Epub 2015/05/08. PubMed Central PMCID: PMC4368144. https://doi.org/10.4161/21624011.2014.965570 PMID: 25949860
11. Economopoulou P, Agelaki S, Perisanidis C, Giotakis EI, Psyrri A. The promise of immunotherapy in head and neck squamous cell carcinoma. Ann Oncol. 2016; 27(9):1675-85. Epub 2016/07/07. https:// doi.org/10.1093/annonc/mdw226 PMID: 27380958
12. Tallon B, Bhawan J. FoxP3 expression is increased in cutaneous squamous cell carcinoma with perineural invasion. J Cutan Pathol. 2010; 37(11):1184-5. Epub 2009/11/20. https://doi.org/10.1111/j. 1600-0560.2009.01482.x PMID: 19922481
13. Chawla S, Warren TA, Wockner LF, Lambie DL, Brown IS, Martin TP, et al. Galectin-1 is associated with poor prognosis in patients with cutaneous head and neck cancer with perineural spread. Cancer Immunol Immunother. 2016; 65(2):213-22. Epub 2016/01/14. https://doi.org/10.1007/s00262-015-1788-z PMID: 26759008
14. Schlosser HA, Theurich S, Shimabukuro-Vornhagen A, Holtick U, Stippel DL, Bergwelt-Baildon M. Overcoming tumor-mediated immunosuppression. Immunotherapy. 2014; 6(9):973-88. Epub 2014/10/24. https://doi.org/10.2217/imt.14.58 PMID: 25341119
15. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015; 348(6230):56-61. Epub 2015/04/04. https://doi.org/10.1126/science.aaa8172 PMID: 25838373
16. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. Epub 2015/06/02. https://doi.org/10.1056/NEJMoa1504030 PMID: 26027431
17. Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discov Med. 2014; 18 (101):341-50. Epub 2015/01/01. PMID: 25549705
18. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010; 207(10):2175-86. Epub 2010/09/08. PubMed Central PMCID: PMC2947081. https://doi.org/10.1084/jem.20100637 PMID: 20819923
19. Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-Targeted Antitumor Immunotherapy. Cancer Res. 2011; 71(21):6567-71. Epub 2011/10/20. https://doi.org/10.1158/0008-5472.CAN-11-1487 PMID: 22009533
20. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol. 2004; 4(3):231-7. Epub 2004/03/25. https://doi.org/10.1038/nri1309 PMID: 15039760
21. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010; 29(8):1093-102. Epub 2009/12/01. https://doi.org/10.1038/onc.2009.416 PMID: 19946335
22. Palucka AK, Coussens LM. The Basis of Oncoimmunology. Cell. 2016; 164(6):1233-47. Epub 2016/ 03/12. PubMed Central PMCID: PMC4788788. https://doi.org/10.1016/j.cell.2016.01.049 PMID: 26967289
23. McKee SJ, Mattarollo SR, Leggatt GR. Immunosuppressive roles of natural killer T (NKT) cells in the skin. J Leukoc Biol. 2014; 96(1):49-54. Epub 2014/05/07. https://doi.org/10.1189/jlb.4RU0114-001R PMID: 24799605
24. Mattarollo SR, Rahimpour A, Choyce A, Godfrey DI, Leggatt GR, Frazer IH. Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production. J Immunol. 2010; 184(3):1242-50. Epub 2009/12/24. https://doi.org/10.4049/jimmunol.0902191 PMID: 20028654
25. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med. 2005; 202(12):1627-33. Epub 2005/12/21. PubMed Central PMCID: PMC2212961. https://doi.org/10.1084/jem.20051381 PMID: 16365146
26. Terabe M, Berzofsky JA. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol. 2007; 28(11):491-6. Epub 2007/10/30. https://doi.org/10.1016/j.it.2007.05.008 PMID: 17964217
27. Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother. 2014; 63 (4):395-406. Epub 2014/02/12. https://doi.org/10.1007/s00262-014-1519-x PMID: 24514954
28. Maine CJ, Aziz NH, Chatterjee J, Hayford C, Brewig N, Whilding L, et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother. 2014; 63(3):215-24. Epub 2013/12/04. https://doi.org/10.1007/s00262-013-1503-x PMID: 24297569
29. Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016; 9:5023-39. Epub 2016/08/31. PubMed Central PMCID: PMC4990391. https://doi.org/10.2147/OTT.S105862 PMID: 27574444
30. Slater NA, Googe PB. PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. J Cutan Pathol. 2016. Epub 2016/05/07.
31. Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 2012; 24 (2):213-6. Epub 2012/01/10. https://doi.org/10.1016/j.coi.2011.12.005 PMID: 22226204
32. Liu H, Zhi L, Duan N, Su P. Abnormal expression of Tim-3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients. FEBS Open Bio. 2016; 6(8):807-15. Epub 2016/08/16. PubMed Central PMCID: PMC4971836. https://doi.org/10.1002/2211-5463.12079 PMID: 27516959
33. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011; 71 (10):3540-51. Epub 2011/03/25. https://doi.org/10.1158/0008-5472.CAN-11-0096 PMID: 21430066
34. Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res. 2016. Epub 2016/07/01.
35. Thommen DS, Schreiner J, Muller P, Herzig P, Roller A, Belousov A, et al. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunol Res. 2015; 3(12):1344-55. Epub 2015/08/09. https://doi.org/10.1158/ 2326-6066.CIR-15-0097 PMID: 26253731
36. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012; 72(4):917-27. Epub 2011/12/22. PubMed Central PMCID: PMC3288154. https://doi.org/10. 1158/0008-5472.CAN-11-1620 PMID: 22186141